Cited by 230Immunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersRNA Interference and Gene Delivery

The DOI matches its Crossref record; 177 of the 179 references it cites were found in a registry or an index.

An RNA toolbox for cancer immunotherapy

Pastor, Fernando, Berraondo, Pedro, Etxeberria, Iñaki, Frederick, Josh, Sahin, Ugur, Gilboa, Eli, Melero, Ignacio·2018·Nature Reviews Drug Discovery

DOI 10.1038/nrd.2018.132

Open this paper in CoChat — free account

Abstract

Cancer immunotherapy has revolutionized oncology practice. However, current protein and cell therapy tools used in cancer immunotherapy are far from perfect, and there is room for improvement regarding their efficacy and safety. RNA-based structures have diverse functions, ranging from gene expression and gene regulation to pro-inflammatory effects and the ability to specifically bind different molecules. These functions make them versatile tools that may advance cancer vaccines and immunomodulation, surpassing existing approaches. These technologies should not be considered as competitors of current immunotherapies but as partners in synergistic combinations and as a clear opportunity to reach more efficient and personalized results. RNA and RNA derivatives can be exploited therapeutically as a platform to encode protein sequences, provide innate pro-inflammatory signals to the immune system (such as those denoting viral infection), control the expression of other RNAs (including key immunosuppressive factors) post-transcriptionally and conform structural scaffoldings binding proteins that control immune cells by modifying their function. Nascent RNA immunotherapeutics include RNA vaccines encoding cancer neoantigens, mRNAs encoding immunomodulatory factors, viral RNA analogues, interference RNAs and protein-binding RNA aptamers. These approaches are already in early clinical development with promising safety and efficacy results.

Integrity signals

Registry

Crossref · 10.1038/nrd.2018.132

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,421
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,845
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
Origins and Mechanisms of miRNAs and siRNAs
Carthew, R. W., & Sontheimer, E. J. (2009) · Cell · doi:10.1016/j.cell.2009.01.035 · Cited by 5,161
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
N6-methyladenosine-dependent regulation of messenger RNA stability
Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., Fu, Y., Parisien, M., Dai, Q., Jia, G., et al. (2014) · Nature · doi:10.1038/nature12730 · Cited by 4,558
Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing
Pan, Q., Shai, O., Lee, L. J., Frey, B. J., & Blencowe, B. J. (2008) · Nature Genetics · doi:10.1038/ng.259 · Cited by 3,951
Unique features of long non-coding RNA biogenesis and function
Quinn, J. J., & Chang, H. Y. (2015) · Nature Reviews Genetics · doi:10.1038/nrg.2015.10 · Cited by 3,700
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Regulation of mRNA Translation and Stability by microRNAs
Fabian, M. R., Sonenberg, N., & Filipowicz, W. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060308-103103 · Cited by 3,214
Argonaute2 is the catalytic engine of mammalian RNAi
Liu, J., Carmell, M. A., Rivas, F. V., Marsden, C. G., Thomson, J. M., Song, J.-J., Hammond, S. M., Joshua-Tor, L., & Hannon, G. J. (2004) · Science · doi:10.1126/science.1102513 · Cited by 2,796
Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Origin of life: The RNA world
Gilbert, W. (1986) · Nature · doi:10.1038/319618a0 · Cited by 2,721
The emerging role of lncRNAs in cancer
Huarte, M. (2015) · Nature Medicine · doi:10.1038/nm.3981 · Cited by 2,712
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
Riaz, N., Havel, J. J., Makarov, V., Desrichard, A., Urba, W. J., Sims, J. S., Hodi, F. S., Martín-Algarra, S., Mandal, R., Sharfman, W. H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.028 · Cited by 2,401
Self-splicing RNA: Autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena
Kruger, K., Grabowski, P. J., Zaug, A. J., Sands, J., Gottschling, D. E., & Cech, T. R. (1982) · Cell · doi:10.1016/0092-8674(82)90414-7 · Cited by 2,331
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,285
RIG-I-mediated antiviral responses to single-stranded RNA bearing 5’-phosphates
Pichlmair, A., Schulz, O., Tan, C. P., Näslund, T. I., Liljeström, P., Weber, F., & Reis e Sousa, C. (2006) · Science · doi:10.1126/science.1132998 · Cited by 2,210
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Interferon-inducible antiviral effectors
Sadler, A. J., & Williams, B. R. G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2314 · Cited by 2,160
Hepatogastroenterology
Xu, D., He, X., Chang, Y., Sun, S., Xu, C., & Lin, J. (2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability
Karikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Long noncoding RNAs: past, present, and future
Kung, J. T. Y., Colognori, D., & Lee, J. T. (2013) · Genetics · doi:10.1534/genetics.112.146704 · Cited by 1,874
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid–inducible gene-I and melanoma differentiation–associated gene 5
Kato, H., Takeuchi, O., Mikamo, E., Hirai, R., Kawai, T., Matsushita, K., Hiiragi, A., Dermody, T. S., Fujita, T., & Akira, S. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080091 · Cited by 1,649
Redefining the invertebrate RNA virosphere
Shī, M., Lin, X., Tian, J.-H., Chen, L., Chen, X., Li, C., Qin, X.-C., Li, J., Cao, J., Eden, J., et al. (2016) · Nature · doi:10.1038/nature20167 · Cited by 1,649
Molecular Basis for the Recognition of Primary microRNAs by the Drosha-DGCR8 Complex
Han, J., Lee, Y., Yeom, K., Nam, J., Heo, I., Rhee, J., Sohn, S. Y., Cho, Y., Zhang, B.-T., & Kim, V. N. (2006) · Cell · doi:10.1016/j.cell.2006.03.043 · Cited by 1,641
An analysis of vertebrate mRNA sequences: intimations of translational control.
Kozak, M. (1991) · The Journal of Cell Biology · doi:10.1083/jcb.115.4.887 · Cited by 1,631
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi
Martînez, J., Patkaniowska, A., Urlaub, H., Lührmann, R., & Tuschl, T. (2002) · Cell · doi:10.1016/s0092-8674(02)00908-x · Cited by 1,480
Distinct and Essential Roles of Transcription Factors IRF-3 and IRF-7 in Response to Viruses for IFN-α/β Gene Induction
Sato, M., Suemori, H., Hata, N., Asagiri, M., Ogasawara, K., Nakao, K., Nakaya, T., Katsuki, M., Noguchi, S., Tanaka, N., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00053-4 · Cited by 1,342
RNA regulons: coordination of post-transcriptional events
Keene, J. D. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2111 · Cited by 1,321
A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,260
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243
Alternative polyadenylation of mRNA precursors
Tian, B., & Manley, J. L. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.116 · Cited by 1,179
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Löwik, M. J. G., der Meer, D. M. A. B.-V., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,101
Codon Optimality Is a Major Determinant of mRNA Stability
Presnyak, V., Alhusaini, N., Chen, Y.-H., Martin, S., Morris, N., Kline, N., Olson, S., Weinberg, D., Baker, K. E., Graveley, B. R., et al. (2015) · Cell · doi:10.1016/j.cell.2015.02.029 · Cited by 1,078
Cell type–specific delivery of siRNAs with aptamer-siRNA chimeras
McNamara, J. O., Andrechek, E. R., Wang, Y., Viles, K. D., Rempel, R. E., Gilboa, E., Sullenger, B. A., & Giangrande, P. H. (2006) · Nature Biotechnology · doi:10.1038/nbt1223 · Cited by 1,020
Multiple Forms of DNA-dependent RNA Polymerase in Eukaryotic Organisms
Roeder, R. G., & Rutter, W. J. (1969) · Nature · doi:10.1038/224234a0 · Cited by 1,001
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
mRNA capping: biological functions and applications
Ramanathan, A., Robb, G. B., & Chan, S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw551 · Cited by 961
Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo.
Boczkowski, D., Nair, S. K., Snyder, D., & Gilboa, E. (1996) · The Journal of experimental medicine · doi:10.1084/jem.184.2.465 · Cited by 915
Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy
Kim, D.-H., Behlke, M. A., Rose, S. D., Chang, M.-S., Choi, S., & Rossi, J. J. (2004) · Nature Biotechnology · doi:10.1038/nbt1051 · Cited by 903
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Qasim, W., Zhan, H., Samarasinghe, S., Adams, S., Amrolia, P., Stafford, S., Butler, K., Rivat, C., Wright, G., Somana, K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaj2013 · Cited by 902
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Nonsense-mediated mRNA decay: an intricate machinery that shapes transcriptomes
Lykke‐Andersen, S., & Jensen, T. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4063 · Cited by 843
Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J. M., Guo, J., Johnson, J. M., Lim, L. P., Karpilow, J. M., Nichols, K. E., et al. (2006) · RNA · doi:10.1261/rna.30706 · Cited by 804
PIWI-Interacting RNA: Its Biogenesis and Functions
Iwasaki, Y. W., Siomi, M. C., & Siomi, H. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034258 · Cited by 796
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W. R., Huber, C., Parmiani, G., Scholl, S., Thatcher, N. J., Wagstaff, J., Zielinski, C. C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 787
Genome-wide measurement of RNA secondary structure in yeast
Kertesz, M., Wan, Y., Mazor, E., Rinn, J. L., Nutter, R. C., Chang, H. Y., & Segal, E. (2010) · Nature · doi:10.1038/nature09322 · Cited by 769
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609243 · Cited by 768
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting
Tacken, P. J., de Vries, I. J. M., Torensma, R., & Figdor, C. G. (2007) · Nature reviews. Immunology · doi:10.1038/nri2173 · Cited by 761
2′-Fluoropyrimidine RNA-based Aptamers to the 165-Amino Acid Form of Vascular Endothelial Growth Factor (VEGF165)
Ruckman, J., Green, L. S., Beeson, J., Waugh, S. M., Gillette, W. L., Henninger, D. D., Claesson, L., & Janjić, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 759
Mechanisms and Consequences of Alternative Polyadenylation
Di Giammartino, D. C., Nishida, K., & Manley, J. L. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.08.017 · Cited by 737
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
Kormann, M. S. D., Hasenpusch, G., Aneja, M. K., Nica, G., Flemmer, A. W., Herber-Jonat, S., Huppmann, M., Mays, L. E., Illenyi, M., Schams, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1733 · Cited by 733
N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice
Andries, O., Mc Cafferty, S., De Smedt, S. C., Weiss, R., Sanders, N. N., & Kitada, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.051 · Cited by 701
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
Bachmaier, K., Krawczyk, C. M., Kozieradzki, I., Kong, Y., Sasaki, T., Oliveira-dos-Santos, A., Mariathasan, S., Bouchard, D., Wakeham, A. C., Itié, A., et al. (2000) · Nature · doi:10.1038/35003228 · Cited by 674
RNA Duplex Map in Living Cells Reveals Higher-Order Transcriptome Structure
Lu, Z., Zhang, Q. C., Lee, B., Flynn, R. A., Smith, M. A., Robinson, J. T., Davidovich, C., Gooding, A. R., Goodrich, K. J., Mattick, J. S., et al. (2016) · Cell · doi:10.1016/j.cell.2016.04.028 · Cited by 647
Detecting RNA modifications in the epitranscriptome: predict and validate
Helm, M., & Motorin, Y. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2016.169 · Cited by 647
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Locke, F. L., Neelapu, S. S., Bartlett, N. L., Siddiqi, T., Chávez, J. C., Hosing, C. M., Ghobadi, A., Budde, L. E., Bot, A. I., Rossi, J. M., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.020 · Cited by 634
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors
Dassie, J. P., Liu, X., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 600
Origins and evolution of viruses of eukaryotes: The ultimate modularity
Koonin, E. V., Dolja, V. V., & Krupovìč, M. (2015) · Virology · doi:10.1016/j.virol.2015.02.039 · Cited by 595
Discriminating self from non-self in nucleic acid sensing
Schlee, M., & Hartmann, G. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.78 · Cited by 594
Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids
Heyes, J., Palmer, L., Bremner, K., & MacLachlan, I. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.014 · Cited by 572
Design of Noninflammatory Synthetic siRNA Mediating Potent Gene Silencing in Vivo
Judge, A. D., Bola, G., Lee, A. C. H., & MacLachlan, I. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.11.002 · Cited by 571
Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors
Heiser, A., Coleman, D., Dannull, J., Yancey, D., Maurice, M. A., Lallas, C. D., Dahm, P., Niedzwiecki, D., Gilboa, E., & Vieweg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214364 · Cited by 562
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes
Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 558
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans
McConkey, S. J., Reece, W. H. H., Moorthy, V., Webster, D. P., Dunachie, S. J., Butcher, G. A., Vuola, J. M., Blanchard, T. J., Gothard, P., Watkins, K., et al. (2003) · Nature Medicine · doi:10.1038/nm881 · Cited by 553
The Nonamer UUAUUUAUU Is the Key AU-Rich Sequence Motif That Mediates mRNA Degradation
Zubiaga, A. M., Belasco, J. G., & Greenberg, M. E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.4.2219 · Cited by 543
Direct Effects of Type I Interferons on Cells of the Immune System
Hervás‐Stubbs, S., Perez‐Gracia, J. L., Rouzaut, A., Sanmamed, M. F., Bon, A. L., & Melero, I. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1114 · Cited by 535
Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents
Rohloff, J. C., Gelinas, A. D., Jarvis, T. C., Ochsner, U. A., Schneider, D. J., Gold, L., & Janjic, N. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.49 · Cited by 533
Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
Alberer, M., Gnad-Vogt, U., Hong, H. S., Mehr, K. T., Backert, L., Finak, G., Gottardo, R., Bica, M. A., Garofano, A., Koch, S. D., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31665-3 · Cited by 530
Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals
Thess, A., Grund, S., Mui, B. L., Hope, M. J., Baumhof, P., Fotin-Mleczek, M., & Schlake, T. (2015) · Molecular Therapy · doi:10.1038/mt.2015.103 · Cited by 513
Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing
Yin, H., Song, C.-Q., Suresh, S., Wu, Q., Walsh, S., Rhym, L. H., Mintzer, E., Bolukbasi, M. F., Zhu, L. J., Kauffman, K., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.4005 · Cited by 499
Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species
Conti, E., & Izaurralde, E. (2005) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2005.04.005 · Cited by 479
Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing
Harborth, J., Elbashir, S. M., Vandenburgh, K., Manninga, H., Scaringe, S. A., Weber, K., & Tuschl, T. (2003) · Antisense and Nucleic Acid Drug Development · doi:10.1089/108729003321629638 · Cited by 474
Establishment of a monoclonal antibody against human Toll-like receptor 3 that blocks double-stranded RNA-mediated signaling
Matsumoto, M., Kikkawa, S., Kohase, M., Miyake, K., & Seya, T. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00380-7 · Cited by 459
Fully 2‘-Modified Oligonucleotide Duplexes with Improved in Vitro Potency and Stability Compared to Unmodified Small Interfering RNA
Allerson, C. R., Sioufi, N. B., Jarres, R., Prakash, T. P., Naik, N., Berdeja, A., Wanders, L., Griffey, R. H., Swayze, E. E., & Bhat, B. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049167j · Cited by 456
Control of Transcriptional Elongation
Kwak, H., & Lis, J. T. (2013) · Annual Review of Genetics · doi:10.1146/annurev-genet-110711-155440 · Cited by 441
Mechanistic insights into precursor messenger RNA splicing by the spliceosome
Shi, Y. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.86 · Cited by 409
Ribozyme-catalyzed transcription of an active ribozyme
Wochner, A., Attwater, J., Coulson, A., & Holliger, P. (2011) · Science · doi:10.1126/science.1200752 · Cited by 399
Mirror-image RNA that binds D-adenosine
Klußmann, S., Nolte, A., Bald, R., Erdmann, V. A., & Fürste, J. P. (1996) · Nature Biotechnology · doi:10.1038/nbt0996-1112 · Cited by 397
Structural basis of transcription initiation by RNA polymerase II
Sainsbury, S., Bernecky, C., & Cramer, P. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3952 · Cited by 397
Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Liang, F., Lindgren, G., Lin, A., Thompson, E. A., Ols, S., Röhss, J., John, S., Hassett, K., Yuzhakov, O., Bahl, K., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.006 · Cited by 395
Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
Bol, K. F., Schreibelt, G., Gerritsen, W. R., de Vries, I. J. M., & Figdor, C. G. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1399 · Cited by 381
The role of mutational robustness in RNA virus evolution
Lauring, A. S., Frydman, J., & Andino, R. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3003 · Cited by 368
Telomerase mRNA-Transfected Dendritic Cells Stimulate Antigen-Specific CD8+ and CD4+ T Cell Responses in Patients with Metastatic Prostate Cancer
Su, Z., Dannull, J., Yang, B. K., Dahm, P., Coleman, D., Yancey, D., Sichi, S., Niedzwiecki, D., Boczkowski, D., Gilboa, E., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3798 · Cited by 359
Untitled work
(2001) · PubMed Central · Cited by 342
Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages
Qian, Y., Qiao, S., Dai, Y., Xu, G., Dai, B., Lu, L., Yu, X. M., Luo, Q., & Zhang, Z. (2017) · ACS Nano · doi:10.1021/acsnano.7b05465 · Cited by 339
Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
Fotin-Mleczek, M., Duchardt, K. M., Lorenz, C., Pfeiffer, R., Ojkić-Zrna, S., Probst, J., & Kallen, K.-J. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181f7dbe8 · Cited by 335
Alternative Splicing of Drosophila Dscam Generates Axon Guidance Receptors that Exhibit Isoform-Specific Homophilic Binding
Wojtowicz, W. M., Flanagan, J. J., Millard, S. S., Zipursky, S. L., & Clemens, J. C. (2004) · Cell · doi:10.1016/j.cell.2004.08.021 · Cited by 332
Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity
Rand, T., Ginalski, K., Grishin, N. V., & Wang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405913101 · Cited by 331
Untitled work
(1995) · PubMed · Cited by 330
Transcription termination by nuclear RNA polymerasesPreprint
Richard, P., & Manley, J. L. (2009) · Genes & Development · doi:10.1101/gad.1792809 · Cited by 326
Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells.
Boczkowski, D., Nair, S. K., Nam, J., Lyerly, H. K., & Gilboa, E. (2000) · PubMed · Cited by 313
Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice
McNamara, J. O., Kolonias, D. S., Pastor, F., Mittler, R. S., Chen, L., Giangrande, P. H., Sullenger, B. A., & Gilboa, E. (2008) · Journal of Clinical Investigation · doi:10.1172/jci33365 · Cited by 311
Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity
Kreiter, S., Selmi, A., Diken, M., Koslowski, M., Britten, C. M., Huber, C., Türeci, Ö., & Sahin, U. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0699 · Cited by 309
Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay
Pastor, F., Kolonias, D. S., Giangrande, P. H., & Gilboa, E. (2010) · Nature · doi:10.1038/nature08999 · Cited by 299
siDirect 2.0: updated software for designing functional siRNA with reduced seed-dependent off-target effect
Naito, Y., Yoshimura, J., Morishita, S., & Ui‐Tei, K. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-392 · Cited by 296
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
Stadler, C. R., Bähr-Mahmud, H., Celik, L., Hebich, B., Roth, A. S., Roth, R. P., Karikó, K., Türeci, Ö., & Sahin, U. (2017) · Nature Medicine · doi:10.1038/nm.4356 · Cited by 290
Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
Kübler, H., Scheel, B., Gnad-Vogt, U., Miller, K., Schultze-Seemann, W., vom Dorp, F., Parmiani, G., Hampel, C., Wedel, S., Trojan, L., et al. (2015) · Journal for Immunotherapy of Cancer · doi:10.1186/s40425-015-0068-y · Cited by 287
Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans
Caskey, M. F., Lefebvre, F., Filali-Mouhim, A., Cameron, M. J., Goulet, J.-P., Haddad, E. K., Breton, G., Trumpfheller, C., Pollak, S., Shimeliovich, I., et al. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20111171 · Cited by 278
N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density
Svitkin, Y. V., Cheng, Y. M., Chakraborty, T., Presnyak, V., John, M., & Sonenberg, N. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx135 · Cited by 278
Quantitative selection of DNA aptamers through microfluidic selection and high-throughput sequencing
Cho, M., Xiao, Y., Nie, J., Stewart, R. M., Csordas, A. T., Oh, S. S., Thomson, J. A., & Soh, H. T. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009331107 · Cited by 268
FASTAptamer: A Bioinformatic Toolkit for High-throughput Sequence Analysis of Combinatorial Selections
Alam, K. K., Chang, J. L., & Burke, D. H. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.4 · Cited by 264
An mRNA Stability Complex Functions with Poly(A)-Binding Protein To Stabilize mRNA In Vitro
Wang, Z., Day, N., Trifillis, P., & Kiledjian, M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4552 · Cited by 262
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and Metastasis
Ajona, D., Ortiz‐Espinosa, S., Moreno, H., Lozano, T., Pajares, M. J., Agorreta, J., Bértolo, C., Lasarte, J. J., Vicent, S., Hoehlig, K., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1184 · Cited by 248
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate
Zimmermann, T. S., Karsten, V., Chan, A., Chiesa, J., Boyce, M. J., Bettencourt, B. R., Hutabarat, R. M., Nochur, S. V., Vaishnaw, A. K., & Gollob, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.019 · Cited by 218
Dendritic cell-targeted vaccines — hope or hype?
Kastenmüller, W., Kastenmüller, K., Kurts, C., & Seder, R. A. (2014) · Nature reviews. Immunology · doi:10.1038/nri3727 · Cited by 216
Systemic Gene Silencing in Primary T Lymphocytes Using Targeted Lipid Nanoparticles
Ramishetti, S., Kedmi, R., Goldsmith, M., Leonard, F., Sprague, A., Godin, B., Gozin, M., Cullis, P. R., Dykxhoorn, D. M., & Peer, D. (2015) · ACS Nano · doi:10.1021/acsnano.5b02796 · Cited by 213
Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy
Lint, S. V., Goyvaerts, C., Maenhout, S. K., Goethals, L., Disy, A., Benteyn, D., Pen, J. J., Bonehill, A., Heirman, C., Breckpot, K., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2957 · Cited by 210
Origin of the RNA world: The fate of nucleobases in warm little ponds
Pearce, B. K. D., Pudritz, R. E., Semenov, D. A., & Henning, T. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710339114 · Cited by 210
Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results
Amin, A., Dudek, A. Z., Logan, T. F., Lance, R. S., Holzbeierlein, J. M., Knox, J. J., Master, V. A., Pal, S. K., Miller, W. H., Karsh, L. I., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0055-3 · Cited by 205
Translating the genome in time and space: Specialized ribosomes, RNA regulons, and RNA-binding proteins
Shi, Z., & Barna, M. (2015) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100814-125346 · Cited by 205
A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients
Wilgenhof, S., Nuffel, A. M. T. V., Benteyn, D., Corthals, J., Aerts, C., Heirman, C., Riet, I. V., Bonehill, A., Thielemans, K., & Neyns, B. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt245 · Cited by 204
The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market
Titze‐de‐Almeida, R., David, C., & Titze-de-Almeida, S. S. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2134-2 · Cited by 203
Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo
Kauffman, K. J., Mir, F. F., Jhunjhunwala, S., Kaczmarek, J. C., Hurtado, J. E., Yang, J. H., Webber, M. J., Kowalski, P. S., Heartlein, M. W., DeRosa, F., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.006 · Cited by 195
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation
Diken, M., Kreiter, S., Selmi, A., Britten, C. M., Huber, C. G., Türeci, Ö., & Şahin, U. (2011) · Gene Therapy · doi:10.1038/gt.2011.17 · Cited by 192
Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity.
Santulli-Marotto, S., Nair, S. K., Rusconi, C. P., Sullenger, B. A., & Gilboa, E. (2003) · PubMed · Cited by 188
Post-SELEX optimization of aptamers
Gao, S., Zheng, X., Jiao, B., & Wang, L. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9556-2 · Cited by 186
Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating Aptamer
Dollins, C. M., Nair, S. K., Boczkowski, D., Lee, J., Layzer, J. M., Gilboa, E., & Sullenger, B. A. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.05.016 · Cited by 183
Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells
Tormo, D., Chęcińska, A., Alonso‐Curbelo, D., Pérez‐Guijarro, E., Cañón, E., Riveiro‐Falkenbach, E., Calvo, T. G., Larribère, L., Megı́as, D., Mulero, F., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.07.004 · Cited by 183
siPools: highly complex but accurately defined siRNA pools eliminate off-target effects
Hannus, M., Beitzinger, M., Engelmann, J. C., Weickert, M., Spang, R., Hannus, S., & Meister, G. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku480 · Cited by 182
The Feedback Phase of Type I Interferon Induction in Dendritic Cells Requires Interferon Regulatory Factor 8
Tailor, P. B., Tamura, T., Kong, H. J., Kubota, T., Kubota, M., Borghi, P., Gabriele, L., & Ozato, K. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.009 · Cited by 179
Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade
Zboralski, D., Hoehlig, K., Eulberg, D., Frömming, A., & Vater, A. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0303 · Cited by 172
Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial
Lincoff, A. M., Mehran, R., Povsic, T. J., Zelenkofske, S. L., Huang, Z., Armstrong, P. W., Steg, P. G., Bode, C., Cohen, M. G., Buller, C. E. H., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00515-2 · Cited by 167
Nucleotide modifications within bacterial messenger RNAs regulate their translation and are able to rewire the genetic code
Hoernes, T. P., Clementi, N., Faserl, K., Glasner, H., Breuker, K., Lindner, H. H., Hüttenhofer, A., & Erlacher, M. D. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1182 · Cited by 166
mRNA transfection of dendritic cells: Synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level
Mockey, M., Gonçalves, C., Dupuy, F. P., Lemoine, F. M., Pichon, C., & Midoux, P. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.105 · Cited by 165
Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer
Caruso, D. A., Orme, L. M., Neale, A. M., Radcliff, F. J., Amor, G. M., Maixner, W., Downie, P., Hassall, T. E., Tang, M. L. K., & Ashley, D. M. (2004) · Neuro-Oncology · doi:10.1215/s1152851703000668 · Cited by 165
MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct
Jain, R., Frederick, J. P., Huang, E. Y., Burke, K. E., Mauger, D. M., Andrianova, E. A., Farlow, S. J., Siddiqui, S., Pimentel, J., Cheung-Ong, K., et al. (2018) · Nucleic Acid Therapeutics · doi:10.1089/nat.2018.0734 · Cited by 164
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells
Herrmann, A., Priceman, S. J., Kujawski, M., Xin, H., Cherryholmes, G. A., Zhang, W., Zhang, C., Lahtz, C., Kowolik, C. M., Forman, S. J., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73174 · Cited by 156
Reprogramming Tumor-Associated Dendritic Cells In Vivo Using miRNA Mimetics Triggers Protective Immunity against Ovarian Cancer
Cubillos‐Ruiz, J. R., Baird, J. R., Tesone, A. J., Rutkowski, M. R., Scarlett, U. K., Camposeco-Jacobs, A. L., Anadon-Arnillas, J., Harwood, N. M., Korc, M., Fiering, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3160 · Cited by 148
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
Türeci, Ö., Vormehr, M., Diken, M., Kreiter, S., Huber, C., & Şahin, U. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1509 · Cited by 148
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
Rodriguez-Ruiz, M. E., Perez‐Gracia, J. L., Rodríguez, I., Alfaro, C., Oñate, C., Pérez, G., Bazo, I. G., Benito, A., Inogés, S., de Cerio, A. L.-D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy089 · Cited by 146
In Vivo Ligands of MDA5 and RIG-I in Measles Virus-Infected Cells
Runge, S., Sparrer, K. M. J., Lässig, C., Hembach, K., Baum, A., García‐Sastre, A., Söding, J., Conzelmann, K., & Hopfner, K. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004081 · Cited by 142
Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens
Boissel, L., Betancur, M., Lu, W., Wels, W. S., Marino, T., Etten, R. A. V., & Klingemann, H. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.634048 · Cited by 138
Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers
Pastor, F., Kolonias, D. S., McNamara, J. O., & Gilboa, E. (2011) · Molecular Therapy · doi:10.1038/mt.2011.145 · Cited by 136
4-1BB agonism: adding the accelerator to cancer immunotherapy
Chester, C., Ambulkar, S. S., & Kohrt, H. E. K. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1829-2 · Cited by 134
CD28 Aptamers as Powerful Immune Response Modulators
Pastor, F., Soldevilla, M. M., Villanueva, H., Kolonias, D. S., Inogés, S., de Cerio, A. L.-D., Kandzia, R., Klimyuk, V. I., Gleba, Y. Y., Gilboa, E., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.26 · Cited by 126
Exploiting poly(I:C) to induce cancer cell apoptosis
Bianchi, F., Pretto, S., Tagliabue, E., Balsari, A., & Sfondrini, L. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1373220 · Cited by 126
Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial
Salazar, A. Μ., Erlich, R. B., Mark, A. S., Bhardwaj, N., & Herberman, R. B. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0024 · Cited by 122
Development of universal antidotes to control aptamer activity
Oney, S., Lam, R. T. S., Bompiani, K. M., Blake, C. M., Quick, G., Heidel, J. D., Liu, J. Y.-C., Mack, B. C., Davis, M. E., Leong, K. W., et al. (2009) · Nature Medicine · doi:10.1038/nm.1990 · Cited by 121
Aptamer-targeted inhibition of mTOR in T cells enhances antitumor immunity
Berezhnoy, A., Castro, I., Levay, A. K., Malek, T. R., & Gilboa, E. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69856 · Cited by 121
Isolation and Optimization of Murine IL-10 Receptor Blocking Oligonucleotide Aptamers Using High-throughput Sequencing
Berezhnoy, A., Stewart, C. A., McNamara, J. O., Thiel, W. H., Giangrande, P. H., Trinchieri, G., & Gilboa, E. (2012) · Molecular Therapy · doi:10.1038/mt.2012.18 · Cited by 119
Type I Interferons Modulate CD8 + T Cell Immunity to mRNA Vaccines
Beuckelaer, A. D., Grooten, J., & Koker, S. D. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.01.006 · Cited by 110
Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies
Melero, I., Murillo, O., Dubrot, J., Hervás‐Stubbs, S., & Perez‐Gracia, J. L. (2008) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2008.05.005 · Cited by 107
Lentiviral vector–based insertional mutagenesis identifies genes associated with liver cancer
Ranzani, M., Cesana, D., Bartholomae, C. C., Sanvito, F., Pala, M., Benedicenti, F., Gallina, P., Sergi, L. S., Merella, S., Bulfone, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2331 · Cited by 105
Selection of Molecular Structure and Delivery of RNA Oligonucleotides to Activate TLR7 versus TLR8 and to Induce High Amounts of IL-12p70 in Primary Human Monocytes
Ablasser, A., Poeck, H., Anz, D., Berger, M., Schlee, M., Kim-Hellmuth, S., Bourquin, C., Goutagny, N., Jiang, Z., Fitzgerald, K. A., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803001 · Cited by 103
Targeting 4-1BB Costimulation to the Tumor Stroma with Bispecific Aptamer Conjugates Enhances the Therapeutic Index of Tumor Immunotherapy
Schrand, B., Berezhnoy, A., Brenneman, R., Williams, A. J., Levay, A. K., Kong, L.-Y., Rao, G., Zhou, S., Heimberger, A. B., & Gilboa, E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0007 · Cited by 97
Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula
Lint, S. V., Wilgenhof, S., Heirman, C., Corthals, J., Breckpot, K., Bonehill, A., Neyns, B., & Thielemans, K. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1558-3 · Cited by 94
The Feasibility and Safety of Immunotherapy with Dendritic Cells Loaded with CEA mRNA Following Neoadjuvant Chemoradiotherapy and Resection of Pancreatic Cancer
Morse, M. A., Nair, S. K., Boczkowski, D., Tyler, D. S., Hurwitz, H. I., Proia, A. D., Clay, T. M., Schlom, J., Gilboa, E., & Lyerly, H. K. (2002) · International Journal of Gastrointestinal Cancer · doi:10.1385/ijgc:32:1:1 · Cited by 91
Regulating type 1 IFN effects in CD8 T cells during viral infections: changing STAT4 and STAT1 expression for function
Gil, M. P., Ploquin, M. J.-Y., Watford, W. T., Lee, S., Kim, K., Wang, X., Kanno, Y., O’Shea, J. J., & Biron, C. A. (2012) · Blood · doi:10.1182/blood-2012-05-428672 · Cited by 88
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
Soldevilla, M. M., Villanueva, H., Bendandi, M., Inogés, S., de Cerio, A. L.-D., & Pastor, F. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.07.020 · Cited by 79
Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer.
Rains, N., Cannan, R. J., Chen, W., & Stubbs, R. S. (2001) · PubMed · Cited by 79
Personalized cancer vaccines: Targeting the cancer mutanome
Zhang, X., Sharma, P. K., Goedegebuure, S. P., & Gillanders, W. E. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.05.073 · Cited by 72
MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells
Soldevilla, M. M., Villanueva, H., Casares, N., Lasarte, J. J., Bendandi, M., Inogés, S., Cerio, A. L.-D. D., & Pastor, F. (2016) · Oncotarget · doi:10.18632/oncotarget.8095 · Cited by 68
Aptamer-targeted Antigen Delivery
Wengerter, B. C., Katakowski, J. A., Rosenberg, J. M., Park, C. G., Almo, S. C., Palliser, D., & Levy, M. (2014) · Molecular Therapy · doi:10.1038/mt.2014.51 · Cited by 64
Cap analogs modified with 1,2-dithiodiphosphate moiety protect mRNA from decapping and enhance its translational potential
Strenkowska, M., Grzela, R., Majewski, M., Wnek, K., Kowalska, J., Łukaszewicz, M., Zuberek, J., Darżynkiewicz, E., Kuhn, A. N., Şahin, U., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw896 · Cited by 63
Hypercostimulation through 4-1BB Distorts Homeostasis of Immune Cells
Lee, S., Salek‐Ardakani, S., Mittler, R. S., & Croft, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803241 · Cited by 62
A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice
Gefen, T., Castro, I., Muharemagic, D., Puplampu-Dove, Y., Patel, S., & Gilboa, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.06.023 · Cited by 61
Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro
Broering, R., Real, C. I., John, M., Jahn‐Hofmann, K., Ickenstein, L. M., Kleinehr, K., Paul, A., Sutter, K., Dittmer, U., Gerken, G., et al. (2013) · International Immunology · doi:10.1093/intimm/dxt040 · Cited by 60
Synthesis, properties, and biological activity of boranophosphate analogs of the mRNA cap: versatile tools for manipulation of therapeutically relevant cap-dependent processes
Kowalska, J., del Nogal, A. W., Darżynkiewicz, Z. M., Buck, J., Nicola, C., Kuhn, A. N., Łukaszewicz, M., Zuberek, J., Strenkowska, M., Ziemniak, M., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku757 · Cited by 56
Targeting inhibition of Foxp3 by a CD28 2′-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy
Lozano, T., Soldevilla, M. M., Casares, N., Villanueva, H., Bendandi, M., Lasarte, J. J., & Pastor, F. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.03.007 · Cited by 56
Aptamer-Targeted Attenuation of IL-2 Signaling in CD8 + T Cells Enhances Antitumor Immunity
Rajagopalan, A. R., Berezhnoy, A., Schrand, B., Puplampu-Dove, Y., & Gilboa, E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.021 · Cited by 53
Identification of TIM3 2′-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy
Hervás‐Stubbs, S., Soldevilla, M. M., Villanueva, H., Mancheño, U., Bendandi, M., & Pastor, F. (2015) · Oncotarget · doi:10.18632/oncotarget.6608 · Cited by 50
Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties
Fioravanti, J., González, I., Medina‐Echeverz, J., Larrea, E., Ardaiz, N., González‐Aseguinolaza, G., Prìeto, J., & Berraondo, P. (2011) · Hepatology · doi:10.1002/hep.24306 · Cited by 44
siRNA and Cancer Immunotherapy
Ghafouri‐Fard, S., & Ghafouri-Fard, S. (2012) · Immunotherapy · doi:10.2217/imt.12.87 · Cited by 42
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
Soldevilla, M. M., Hervás, S., Villanueva, H., Lozano, T., Rabal, O., Oyarzábal, J., Lasarte, J. J., Bendandi, M., Inogés, S., de Cerio, A. L.-D., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185169 · Cited by 42
Endonuclease-Mediated mRNA Decay Involves the Selective Targeting of PMR1 to Polyribosome-Bound Substrate mRNA
Yang, F., & Schoenberg, D. R. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.05.001 · Cited by 39
Radiation-Induced Enhancement of Antitumor T-cell Immunity by VEGF-Targeted 4-1BB Costimulation
Schrand, B., Verma, B., Levay, A. K., Patel, S., Castro, I., Benaduce, A. P., Brenneman, R., Umland, O., Yagita∥, H., Gilboa, E., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2105 · Cited by 38
Direct and indirect antitumor effects by human peripheral blood lymphocytes expressing both chimeric immune receptor and interleukin-2 in ovarian cancer xenograft model
Lee, J. M., Yoon, S. H., Kim, H.-S., Kim, S. Y., Sohn, H.-J., Oh, S.-T., Ih, O., & Kim, T.-G. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2010.30 · Cited by 14
Interim analysis of the phase 3 ADAPT trial evaluating rocapuldencel-T (AGS-003), an individualized immunotherapy for the treatment of newly-diagnosed patients with metastatic renal cell carcinoma (mRCC)
Figlin, R. A., Nicolette, C. A., Tannir, N. M., Tykodi, S. S., Chen, D., Master, V. A., Lane, B. R., Debenedette, M. A., Monesmith, T., Tan, W. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx376.003 · Cited by 12
Regado's aptamer lines up against anticoagulants
Sinha, G. (2013) · Nature Biotechnology · doi:10.1038/nbt1213-1060 · Cited by 5

Flagged first, then by citations

2 of the 179 references couldn’t be matched to a known paper.

Sorted by citations

Enhancing cancer immunotherapy with nanomedicine
Irvine, D. J., & Dane, E. L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-019-0269-6 · Cited by 908
Chemistry, structure and function of approved oligonucleotide therapeutics
Egli, M., & Manoharan, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad067 · Cited by 909
Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects
Montoto, S. S., Muraca, G., & Ruiz, M. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.587997 · Cited by 695
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 527
mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases
Maruggi, G., Zhang, C., Li, J., Ulmer, J. B., & Yu, D. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.020 · Cited by 507

See all 230

Authors: Pastor, F., Berraondo, P., Etxeberria, I., Frederick, J., Sahin, U., Gilboa, E., & Melero, I.
Affiliations: Centro de Investigación Médica Aplicada (ES)
Navarre Institute of Health Research (ES)
Moderna Therapeutics (United States) (US)
University of Miami (US)
Corresponding author: Melero, Ignacio
ORCID: Pastor, Fernando
Berraondo, Pedro
Gilboa, Eli
Melero, Ignacio
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2018-09-07
Volume: 17
Issue: 10
Pages: 751-767
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd.2018.132
OpenAlex: W2889813782
Cited by: 229
References: 179
Citations by year: 2026: 11 · 2025: 27 · 2024: 24 · 2023: 39 · 2022: 40 · 2021: 33 · 2020: 27 · 2019: 27 · 2018: 1
FWCI: 2.25
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords: cancer immunotherapy, RNA vaccines, neoantigens, mRNA vaccines, RNA interference, RNA aptamers, immunomodulation, innate immune activation, post-transcriptional regulation, cancer vaccines, combination immunotherapy
MeSH terms: Animals, Humans, Immunotherapy, Neoplasms, RNA, Cancer Vaccines, RNA Interference, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

An RNA toolbox for cancer immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks